000			02955nam a22003375i 4500
001			82467
003			ES-MaUEC
005			20230207040412.0
007			cr nn 008mamaa
008			150629s2015 gw | s |||| 0|eng d
020			_a9783319204338
040			_aES-MaUEC
050		4	_aRC632.D87 _b2015 EB
082	0	4	_a616.12
245	0	0	_aCombination Therapy In Dyslipidemia _cedited by Maciej Banach
260			_aCham _bSpringer International Publishing _bImprint: Adis _c2015
300			_a1 recurso en línea (VIII, 205 p.) 22 il., 15 il. col.
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
338			_aonline resource _bcr _2rdacarrier
520			_aComprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP), and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia.
942			_2lcc _cLE
650		7	_aLipoproteínas _xMetabolismo _xTrastornos _9384873 _0comprobar BNE20062203085 _2embne
700	1		_aBanach, Maciej _eeditor literario _995430 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-20433-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12911070 _b10-10-17 _c10-02-16
988			_aSpringer_Medicine_2015
998			_am _a_alco _a_vill _b14-12-16 _cm _dz _ea _feng _ggw _h0
945			_aRC632.D87 C663 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11578750 _z06-04-17
999			_c82467 _d82467 _x1